Canadian Lab Creates First Human Campylobacter Vaccine

After 20 years of research, scientists at the University of Guelph have successfully tested the world's first human vaccine against Campylobacter jejuni, a bacteria lurking in undercooked chicken that causes devastating diarrhea worldwide.

The Phase 1 trial tested about 60 healthy adults between 2022 and 2024, and the results exceeded expectations. Not only was the vaccine safe, but it raised protective antibodies in participants with minimal side effects like muscle soreness and fatigue at the injection site.

Dr. Mario Monteiro, who led the vaccine development, was thrilled by an unexpected discovery. The lowest dose of the vaccine produced the strongest immune response, making it easier to create a single shot that protects against multiple strains of the bacteria at once.

Campylobacter jejuni ranks among the top bacterial causes of diarrheal illness globally, triggering severe symptoms that last for days. Left untreated, infections can turn deadly, like an outbreak in India last year that killed 11 people from contaminated water.

Children in developing countries face the highest risk, along with anyone with a weakened immune system. Travelers of any age could benefit from protection against this common food poisoning culprit.

The vaccine also offers an unexpected bonus by preventing Guillain-Barré syndrome, a severe autoimmune disorder that often appears after a Campylobacter infection.

What makes this breakthrough special is the science behind it. While most vaccines target proteins, Monteiro's lab focuses on the sugar molecules coating bacterial cells, a complex and time-consuming approach that few researchers attempt.

The strategy paid off after an earlier 2014 trial fell short. Monteiro's team discovered a crucial sugar molecule was missing from their first formula, so they rebuilt the vaccine from scratch with the correct ingredients.

This marks the fourth human trial for vaccines discovered in Monteiro's lab, which has gained worldwide recognition for pioneering sugar-based vaccine technology. The World Health Organization even named it a preferred product against antibiotic-resistant bacteria, calling drug resistance a "hidden pandemic."

The Ripple Effect

The vaccine represents more than two decades of collaboration between Canadian researchers and the U.S. Naval Medical Research Center. David Hobson from the University of Guelph's Research Innovation Office has been working to connect the lab with industry partners who can manufacture and distribute the vaccine globally.

Next comes a Phase 2 trial with hundreds of volunteers to test whether the immune response actually prevents illness in real-world conditions.

For Monteiro and his students, the daily joy comes from discovering new molecules in the lab, but reaching pharmacy shelves means something bigger: countless lives saved from a preventable illness that still devastates communities worldwide.